Hualan Biological Bacterin Inc
SZSE:301207
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.63
31.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hualan Biological Bacterin Inc
Cash & Cash Equivalents
Hualan Biological Bacterin Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hualan Biological Bacterin Inc
SZSE:301207
|
Cash & Cash Equivalents
¥641m
|
CAGR 3-Years
16%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash & Cash Equivalents
¥15B
|
CAGR 3-Years
33%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash & Cash Equivalents
¥2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash & Cash Equivalents
¥3.8B
|
CAGR 3-Years
75%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
38%
|
CAGR 10-Years
20%
|
|
Hualan Biological Bacterin Inc
Glance View
Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
See Also
What is Hualan Biological Bacterin Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
641m
CNY
Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Cash & Cash Equivalents amounts to 641m CNY.
What is Hualan Biological Bacterin Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
35%
Over the last year, the Cash & Cash Equivalents growth was 7%. The average annual Cash & Cash Equivalents growth rates for Hualan Biological Bacterin Inc have been 16% over the past three years , 35% over the past five years .
You don't have any saved screeners yet
